Clinicopathological features, survival and risk in breast cancer survivors with thyroid cancer: an analysis of the SEER database

Shuting Li, Jiao Yang, Yanwei Shen, Xiaoei Zhao, Lingxiao Zhang, Biyuan Wang, Pan Li, Yunmei Wang, Min Yi and Jin Yang

Abstract

Background: The co-occurrence of breast cancer (BC) and thyroid cancer (TC) has been mentioned for several years, researchers observed an increased risk of BC patients to develop TC, but few researches concern about the features, survival of BC patients followed by TC and the influent factors of the incidence risk. The present study aimed to estimate the clinicopathological features, survival of BC survivors who had primary TC and the predictive factors on the risk of BC patients to develop TC.

Methods: Women diagnosed with BC between 1992 and 2011, and then developed TC from the Surveillance, Epidemiology, and End Results Database were included. Standardized incidence ratios (SIRs) was used to perform multiple primary analyses, generated from the multiple primary-SIR program in SEER*Stat.

Results: A total of 842 BC then TC patients were included, the median age was 54 years. Additionally, 78.39% were white, 60.45% had T1 cancer, 62.47% had negative lymph nodes, and more than 75% had infiltrating duct carcinoma, 5-year survival rate was 95.4%. Compared with BC only patients, they were younger, had smaller tumor size and a relatively better prognosis. The risk of developing TC was higher in BC patients than in the general population (SIR 1.22, 95% CI [1.14, 1.31]), especially within 3 years. The influent factors of SIR were black race, BC tumor site, grade and ER/PR positive expression.

Conclusions: BC patients followed by TC had its particular clinicopathological features. Compared with the features and survival of BC only patients, they were younger, had a smaller tumor size and a relatively better prognosis. Furthermore, BC patients had a high risk of developing TC, especially within 3 years. Black women, primary tumor located in an upper-outer, central, or overlapping site, high grade tumor and with positive hormone receptor expression were predictive factors to develop TC.

Keywords: Breast cancer, Thyroid cancer, Clinicopathological features, Survival, Standardized incidence ratios

Introduction

According to the 2012 GLOBOCAN statistics, breast cancer (BC) is the second most common cancer overall and the most frequently diagnosed cancer in women, with 1.67 million women diagnosed with BC worldwide [1]. Because of the high rate of survival and the relatively young age at diagnosis, the number of BC survivors is increasing, and therefore, there is a chance of experiencing other cancers. Five most common cancers occurred in BC survivors are contralateral breast cancer (cumulative incidence at 8 years is 1.64%), urinary system cancer (0.43%), lung cancer (0.31%), thyroid cancer (0.28%) and melanoma (0.21%) [2]. Several articles have suggested that BC and thyroid cancer (TC) can occur together in female patients, and the rate of occurrence is much higher than that expected by chance [3]. Studies have evaluated the risk of developing second primary malignancies in patients with BC or TC history [2, 4–6], an increased risk of developing TC in BC survivors was observed. It is suspected that BC and TC share some common etiological factors [7–9], and some treatment-related factors may...
play a role in its co-occurrence. Besides, study on the comparison of features and prognosis between BC patients with TC and TC only patients was conducted [10]. However, few studies focused on the differences on clinicopathological features and prognosis between BC survivors with TC and BC only patients, the factors that influence the risk of BC survivors to develop TC is unclear.

The present study aimed to estimate the clinicopathological features, survival, risk and influential factors of SIRs on BC survivors followed by primary TC by analyzing the Surveillance, Epidemiology, and End Results (SEER) Database.

Materials and methods
Data source
Data were obtained from 13 US registration centers in the SEER Database, a database programed by US National Cancer Institute, which collects, processes, and provides data on approximately 10% of the US population, using the SEER*Stat software program (version 8.3.2; http://seer.cancer.gov/seerstat; accessed April 14, 2016) under a user agreement. In order to obtain data of BC patients who subsequently developed TC and had the follow-up records for at least 2 years until 2013, we used the database to identify patients whose primary tumor site codes were C50.0–C50.9, and histology codes were 8500/3 (infiltrating duct carcinoma), 8520/3 (lobular carcinoma), 8521/3 (infiltrating ductular carcinoma), 8522/3 (infiltrating duct and lobular carcinoma), 8523/3 (infiltrating duct mix with other types of carcinoma), 8524/3 (infiltrating lobular mix with other types of carcinoma), and 8541/3 (Paget disease and infiltrating ductal carcinoma of breast) from 1992 to 2011. Considering the opinion accepted by most scholars that occurrence of 2 types of cancers within 6 months is mainly considered as simultaneous occurrence, the latency between BC and TC was required at least 6 months. BC only cohort also met the site codes, histology codes and follow-up years criteria mentioned above, but the number of primary malignancies was only one.

A total of 842 cases matched the criteria and composed of BC then developing TC cohort, 332,424 patients composed of BC only cohort. All patients were followed until last known follow-up, death, or December 31, 2013, whichever occurred first. Data, including basic patient information, clinical features, pathologic characteristics, standard incidence rates, and survival information, were collected.

Statistical methods
Overall survival (OS) was defined as the time from the diagnosis of BC to the time of death from any cause or loss of contact. OS curves were calculated using the Kaplan-Meier method. Cox proportional hazards models were used to evaluate the influence of collected clinicopathological factors on OS of BC then TC patients. Different factors have different impact on patients’ survival, after adjusting for the influence of other factors, a certain factor may have individual impact on survival, reflecting on the p value<0.05 in Cox proportional hazards models, this factor was known as a prognostic factor. The standardized incidence ratios (SIRs) was used to perform multiple primary analyses, generated from the multiple primary-SIR program in SEER*Stat (version 8.3.2; April 14, 2016). SIR was used to compare the incidence rate for the cohort of patients previously diagnosed with BC and subsequently diagnosed with TC to that expected in the general population. SIR = standardized incidence rate of BC patients to develop TC / standardized incidence rate of general population to develop TC. SIR>1 means BC patients have more risk to develop TC than general women, factors with a SIR>1 and p value<0.05 was known as a predictive factor. Statistical analyses were performed using SPSS version 21.0 (IBM Corp., Armonk, NY, USA). All statistical tests were two-tailed, and p < 0.05 was considered significant.

Results

Differences between the clinicopathological features of BC then TC group and BC only group
Clinicopathological features of BC then TC group and BC only group are presented in Table 1. With regard to the features of BC patients followed by TC, more than half of the patients were more than 50 years when diagnosed with BC, and the largest age group was 51–60 years, only 11.28% of the BC survivors with primary TC were diagnosed before 40 years of age. Regarding race, white women represented 78.39% of the patients, which mainly due to the composition of the population. Regarding other pathological features, more than 1/3 of the patients had BC in the upper-outer quarter, 60.45% had T1 cancer, 62.47% had negative lymph nodes, more than 3/4 had infiltrating duct carcinoma, more than 1/3 had grade 2 or 3 histology, and more than half were hormone receptor-positive cancer. Compared these features with those of BC only patients, some particular features were obtained. BC patients followed by TC showed a significantly younger median age at diagnosis (54 vs 59, p < 0.001) and accordingly had more patients of <50 years group (37.41% vs 28.58%). Considering tumor features, BC sizes between two groups were significantly different, BC patients followed by TC had more small size (T ≤ 20 mm) tumors.

Survival and survival influential factors of BC patients followed by TC
Kaplan-Meier curves were used to demonstrate the OS curves. The 5-year OS rate of BC then TC patients was 95.4%, BC only patients was 88.9%.
Table 1: Clinicopathological features of 842 breast cancer patients followed by thyroid cancer and 332,424 breast cancer only patients

| Age at diagnosis          | Breast cancer then develop thyroid cacer, $n = 842$ | Breast cancer only, $n = 332,424$ | p-value |
|---------------------------|----------------------------------------------------|----------------------------------|---------|
| Median age (years)        | 54 [47, 63]                                        | 59 [49, 71]                      | < 0.001 |
| ≤ 40                      | 95                                                 | 25,787                           | 7.76%   |
| 41–50                     | 220                                                | 69,214                           | 20.82%  |
| 51–60                     | 257                                                | 80,754                           | 24.29%  |
| 61–70                     | 172                                                | 70,475                           | 21.20%  |
| > 70                      | 98                                                 | 86,194                           | 25.93%  |
| Race                      |                                                    |                                  | 0.106   |
| White                     | 660                                                | 267,366                          | 80.43%  |
| Black                     | 77                                                 | 30,469                           | 9.17%   |
| American Indian           | 6                                                  | 2,267                            | 0.68%   |
| Asian or Pacific Islander | 97                                                 | 30,311                           | 9.12%   |
| Unknown                   | 2                                                  | 2,011                            | 0.60%   |
| Tumor site                |                                                    |                                  | 0.912   |
| Central portion           | 55                                                 | 18,578                           | 5.59%   |
| Nipple                    | 3                                                  | 1,889                            | 0.66%   |
| Upper-inner               | 90                                                 | 34,580                           | 10.40%  |
| Lower-inner               | 44                                                 | 17,684                           | 5.32%   |
| Upper-outter              | 301                                                | 116,708                          | 35.11%  |
| Lower-outter              | 56                                                 | 22,500                           | 6.77%   |
| Overlapping lesion        | 167                                                | 68,460                           | 20.59%  |
| Unknown                   | 126                                                | 52,033                           | 15.65%  |
| Tumor size                |                                                    |                                  | < 0.001 |
| T ≤ 20 mm                 | 509                                                | 186,656                          | 56.15%  |
| 21 mm < T ≤ 50 mm         | 235                                                | 88,752                           | 26.70%  |
| T > 50 mm                 | 39                                                 | 14,467                           | 4.35%   |
| Unknown                   | 59                                                 | 42,553                           | 12.80%  |
| Positive lymph nodes      |                                                    |                                  | 0.358   |
| 0                         | 526                                                | 198,449                          | 59.70%  |
| 1–3                       | 174                                                | 71,560                           | 21.53%  |
| 4–9                       | 55                                                 | 22,700                           | 6.83%   |
| ≥ 10                      | 27                                                 | 14,593                           | 4.38%   |
| Unknown                   | 60                                                 | 25,127                           | 7.56%   |
| Histology                 |                                                    |                                  | 0.650   |
| Infiltrating duct carcinoma| 689                                                | 267,864                          | 80.57%  |
| Lobular carcinoma         | 71                                                 | 29,570                           | 8.90%   |
| Mixed                     | 82                                                 | 34,993                           | 10.53%  |
| Grade                     |                                                    |                                  | 0.351   |
| 1                         | 136                                                | 56,672                           | 17.05%  |
| 2                         | 350                                                | 130,229                          | 39.18%  |
| 3                         | 283                                                | 111,645                          | 33.58%  |
| 4                         | 13                                                 | 4636                             | 1.39%   |
Cox proportional hazards models were used to evaluate the influence of collected clinicopathological factors on OS of patients developed TC after BC diagnosis, results are summarized in Table 2. After adjusting for the influence of other factors, \( p \text{-value} < 0.05 \) in Cox proportional hazards models indicates this factor as a prognostic factor, which means BC then TC patients with this feature have an increased probability to get a worse prognosis. In Table 2, After adjusting for the influence of other factors, the age at diagnosis of BC \( (p < 0.001) \) and the number of positive lymph nodes \( (p < 0.001) \) were prognostic factors of BC patients followed by TC. With regard to age, using \( \leq 40 \) years as a reference, \( 61–70 \) and \( > 70 \) age groups had a relatively worse prognosis. With regard to lymph nodes, when zero positive metastatic lymph nodes was used as a reference, with the increase in the number of positive metastatic lymph nodes, the shorter OS was obtained.

In order to determine the lowest cut-off age that could indicate a significantly different prognosis, the contiguous age with different survival was analyzed in SPSS, and 43 years of age was identified as the lowest cut-off age with significantly different prognosis on both sides \( (p = 0.022) \). Considering the utility in clinic, 50 years was selected as the cut-off age finally, survival curves were summarized in Fig. 1. Two separate OS curves were represented in Fig. 1 when grouped by age 50, patients younger than 50 exhibited a significant advantage for OS. Figure 2 demonstrates the survival curves of different positive lymph node number groups, and 5 separate curves were noted in the figure \( (p < 0.001) \). With the

| Variable                  | HR (CI)       | \( p \)-value |
|---------------------------|---------------|---------------|
| Age at diagnosis          |               | < 0.001       |
| \( \leq 40 \)              | Reference     |               |
| 41–50                     | 1.158 (0.519–2.582) | 0.720         |
| 51–60                     | 1.613 (0.737–3.533) | 0.232         |
| 61–70                     | 4.940 (2.306–10.585) | < 0.001       |
| > 70                      | 11.681 (5.409–25.225) | < 0.001       |
| Race                      |               | 0.279         |
| Tumor site                |               | 0.520         |
| Tumor size                |               | 0.096         |
| Positive lymph nodes      |               | < 0.001       |
| 0                         | Reference     |               |
| 1–3                       | 1.649 (1.049–2.591) | 0.030         |
| 4–9                       | 2.440 (1.235–4.821) | 0.010         |
| \( \geq 10 \)             | 6.515 (3.106–13.663) | < 0.001       |
| Unknown                   | 2.054 (1.200–3.417) | 0.009         |
| Histology                 |               | 0.125         |
| Grade                     |               | 0.321         |
| ER                        |               | 0.831         |
| PR                        |               | 0.767         |

**Table 1** Clinicopathological features of 842 breast cancer patients followed by thyroid cancer and 332,424 breast cancer only patients (Continued)

|              | Breast cancer then develop thyroid cancer, \( n = 842 \) | Breast cancer only, \( n = 332,424 \) | \( p \)-value |
|--------------|--------------------------------------------------------|-------------------------------------|---------------|
| Unknown      | 60                                                     | 29,247                             | 8.80%         |
| ER           | 0.908                                                  | 234,140                            | 70.43%        |
| Positive     | 601                                                    | 1,97,737                           | 59.48%        |
| Negative     | 155                                                    | 62,340                             | 18.76%        |
| Borderline   | 2                                                      | 1062                               | 0.32%         |
| Unknown      | 84                                                     | 34,882                             | 10.49%        |
| PR           | 0.090                                                  | 92,509                             | 27.83%        |
| Positive     | 532                                                    | 197,737                            | 59.48%        |
| Negative     | 202                                                    | 92,509                             | 27.83%        |
| Borderline   | 6                                                      | 2069                               | 0.62%         |
| Unknown      | 102                                                    | 40,113                             | 12.07%        |
| HER-2        | 0.061                                                  | 2.054 (1.200–3.417)                | 0.009         |

**ER** Estrogen receptor, **PR** Progesterone receptor, **HER-2** Human epidermal growth factor receptor 2

HR Hazard ratio, CI Confidence interval, ER Estrogen receptor, PR Progesterone receptor
increase of positive lymph nodes number, a worse prognosis was obtained.

SIR and SIR influent factors of BC patients followed by TC

In our study, the SIR was used to compare the incidence rate for the cohort of patients previously diagnosed with BC and subsequently diagnosed with TC to that expected in the general population. SIR> 1 means BC patients have more risk to develop TC than general women. We compared the standardized incidence rate of BC patients with a certain feature with that of general women with the same feature, when the ratio (SIR) > 1 and \( p \) value<0.05, this feature was defined as a predictive factor, which indicates that BC patients with this feature had an increased probability to further develop TC. The SIR values were generated from the multiple primary-SIR program in SEER*Stat and results are summarized in Fig. 3 and Table 3. The SIR for develop TC was 1.22 (95% CI [1.14, 1.31]) in total.

The mean latency from diagnosis with BC to the development of TC was 65.7 months. The incidence of developing primary TC was significantly high within the first 3 years of BC diagnosis and then decreased, with no significantly difference from that of the general population (Fig. 3). Therefore, a latency of 3 years was used as the cut-off when evaluating the influence of other factors in Table 3.

Different influent factors were summarized in Table 3, when SIR > 1 and \( p \) value<0.05, this factor was defined as a predictive factor, which indicates that BC patients with this feature had an increased probability to further develop TC. When considering race, white, black, Asian, and Pacific Islander patients all had significant high SIRs. Black women with BC had the highest SIR of 1.88, and even beyond the 3-year latency, the risk was still higher in these patients to develop TC than in general black women (SIR 1.56, 95% CI [1.14, 2.09]). The excess risk of black women was 1.61 per 10,000 persons, which was the highest in all SIR influent factors. With regard to the site of BC, tumors located in upper-outer quarter or central portion or overlapping lesions showed a significant increase in the risk of TC development (SIRs were 1.48, 1.19, and 1.19, respectively). BC patients with high grade (grade 2 or 3) tumor also had significantly higher...

![Fig. 1](image-url) Survival curves for an age 50 cut-off of 842 breast cancer patients followed by thyroid cancer
**Fig. 2** Survival curves for different positive lymph node numbers of 842 breast cancer patients followed by thyroid cancer.

**Fig. 3** Incidence rate ratios of 842 breast cancer patients followed by thyroid cancer, stratified by time interval.
risk to develop TC. With regard to the status of hormone receptors, BC survivors were at a significantly high risk for developing TC when both the estrogen receptor (ER) and progesterone receptor (PR) were positive (SIR 1.26, 95% CI [1.15, 1.37]). But when only considered the SIR within 3 years of BC diagnosis, all BC survivors had a significantly high incidence to develop TC irrespective of ER or PR status.

**Discussion**

The possibility of a relation between BC and thyroid diseases has been considered for several years, and the foundation of this opinion is the breasts and thyroid are hormone responsive organs, which are closely related to endocrine function changes and glandular diseases [11]. One of the first studies to suggest this relationship was the study by Beatson [12] in 1896, in which thyroid extract was used in the treatment of BC. Then, studies have evaluated the risk of developing second primary malignancies in patients with BC or TC history [2, 4–6], mainly concentrate on the influence of radiotherapy.

Some studies demonstrated that BC patients have more chance to develop second primary TC and vise versa [3, 7, 9]. Few studies have focused on the features and survival of BC survivors with TC and the factors that influence the risk of BC survivors to develop TC. Our study is novel in that it focused on the clinicopathological features, survival, and predictive factors of BC survivors who developed primary TC, based on the cohorts from the SEER database.

Table 1 shows that patients with both BC and TC were more likely to be white, have a median age of 54 years, have a tumor size less than 2 cm, have no lymph nodes metastasis, show infiltrating duct pathology, show grade 2 or 3 histology, and with hormone receptors positivity. In a previous study, An et al. [3] investigated 81 BC patients followed by TC, median age at diagnosis of BC was 43.4, 86.5% BC were infiltrating duct carcinoma and ER, PR expressions increased significantly in BC patients. The present results are consistent with these above. Additionally, compared the clinicopathological features and prognosis with those of BC only patients,

| Variable       | Total          | 6–36 months | > 36 months |
|----------------|----------------|-------------|-------------|
|                | Observed | SIR         | CI low | CI high | Excess risk | Observed | SIR | CI low | CI high | Observed | SIR | CI low | CI high |
| Race           |          |             |        |         |             |          |     |        |         |          |     |        |         |
| White          | 660      | 1.15*       | 1.06  | 1.24    | 0.37        | 263      | 1.67**| 1.47  | 1.88    | 397      | 0.95 | 0.86  | 1.05    |
| Black          | 77       | 1.88**      | 1.48  | 2.34    | 1.61        | 32       | 2.63**| 1.80  | 3.71    | 45       | 1.56*| 1.14  | 2.09    |
| Asian or Pacific Islander | 97 | 1.46  | 1.18  | 1.78    | 1.19        | 43       | 2.19  | 1.59  | 2.95    | 54       | 1.15 | 0.87  | 1.51    |
| Site           |          |             |        |         |             |          |     |        |         |          |     |        |         |
| Central portion| 55       | 1.48*       | 1.12  | 1.93    | 1.13        | 28       | 2.76**| 1.84  | 3.99    | 27       | 1.00 | 0.66  | 1.45    |
| Upper-inner    | 90       | 1.23        | 0.99  | 1.51    | 0.56        | 32       | 1.53  | 1.05  | 2.16    | 58       | 1.11 | 0.84  | 1.43    |
| Lower-inner    | 44       | 1.20        | 0.87  | 1.62    | 0.49        | 17       | 1.64  | 0.96  | 2.63    | 27       | 1.03 | 0.68  | 1.50    |
| Upper-outer    | 301      | 1.19*       | 1.06  | 1.33    | 0.46        | 112      | 1.65  | 1.36  | 1.98    | 189      | 1.02 | 0.88  | 1.18    |
| Lower-outer    | 56       | 1.20        | 0.91  | 1.56    | 0.50        | 20       | 1.50  | 0.92  | 2.32    | 36       | 1.08 | 0.76  | 1.50    |
| Overlapping lesion | 167 | 1.19* | 1.02  | 1.39    | 0.48        | 82       | 2.04**| 1.63  | 2.54    | 85       | 0.85 | 0.68  | 1.05    |
| Grade          |          |             |        |         |             |          |     |        |         |          |     |        |         |
| 1              | 136      | 1.12        | 0.94  | 1.33    | 0.31        | 45       | 1.26  | 0.92  | 1.68    | 91       | 1.07 | 0.86  | 1.31    |
| 2              | 350      | 1.27*       | 1.14  | 1.41    | 0.66        | 134      | 1.72* | 1.44  | 2.04    | 216      | 1.09 | 0.95  | 1.25    |
| 3              | 283      | 1.30*       | 1.16  | 1.47    | 0.76        | 135      | 2.16**| 1.81  | 2.56    | 148      | 0.96 | 0.81  | 1.12    |
| ER             |          |             |        |         |             |          |     |        |         |          |     |        |         |
| Positive       | 601      | 1.24*       | 1.14  | 1.34    | 0.59        | 242      | 1.71* | 1.50  | 1.94    | 359      | 1.04 | 0.94  | 1.16    |
| Negative       | 155      | 1.25*       | 1.06  | 1.47    | 0.63        | 72       | 2.10**| 1.65  | 2.65    | 83       | 0.93 | 0.74  | 1.15    |
| PR             |          |             |        |         |             |          |     |        |         |          |     |        |         |
| Positive       | 532      | 1.27*       | 1.17  | 1.39    | 0.68        | 216      | 1.79**| 1.56  | 2.04    | 316      | 1.06 | 0.95  | 1.19    |
| Negative       | 202      | 1.15        | 0.99  | 1.32    | 0.36        | 92       | 1.78* | 1.44  | 2.19    | 110      | 0.88 | 0.71  | 1.06    |
| ER (+) PR (+)  | 507      | 1.26*       | 1.15  | 1.37    | 0.64        | 206      | 1.75**| 1.52  | 2.01    | 301      | 1.05 | 0.94  | 1.18    |
| ER (−) PR (−)  | 125      | 1.16        | 0.96  | 1.38    | 0.40        | 61       | 1.97  | 1.51  | 2.53    | 64       | 0.83 | 0.64  | 1.06    |

SIR: Standardized incidence ratio, CI: Confidence interval, ER: Estrogen receptor, PR: Progesterone receptor
*p < 0.05; **p < 0.01
BC patients followed by TC were younger, had a significantly smaller tumor size, and had a relatively better prognosis. An earlier age at diagnosis, a smaller tumor and a well prognosis increased the chance of developing a second tumor in the following years, which few studies have mentioned before. With regard to the better prognosis of BC survivors with TC, it mainly due to the early age at diagnosis, the 10-year survival of TC patients reaching 95–97% [9] was another reason. Considering the factors that influence the survival of patients with both BC and TC, age at diagnosis of BC and the number of positive lymph nodes were identified after adjustment, and these are known to be prognostic factors in BC only patients [13], seeming there is no much difference existed. As a clinician, by using these prognosis factors, we are able to identify patients who may get a worse survival, which give us a chance to make effort to improve their prognosis at the time of diagnosis or during patients’ therapy.

The SIR for develop TC was 1.22 (95% CI [1.14, 1.31]) in total, results from other studies range from 1.28 to 2.18 [3, 7, 14, 15]. The significantly high SIR indicated BC patients had an increased risk for developing TC, which was not just the result of increased medical surveillance for breast cancer. Hormonal, genetic, and environmental factors, and treatment modalities might play roles in this co-occurrence [3, 9, 14, 16]. Moreover, a common molecular mechanism might exist, rather than an incidental association. Researchers proposed ER/PR signaling might represent common etiological factors in the development of TC and BC, studies on the mechanism, including the ER pathway in thyroid tissues and mutations in the CHEK2 gene, have been reported previously [3, 14, 17]. Clinicopathological features in BC then TC group also showed a tendency in more positive expression of ER/PR than BC only group in Table 1. Several articles evaluating radiotherapy after BC diagnosis as a possible cause of the increased risk of second primary TC. Grantzau [4] conducted a meta-analysis of 762,468 BC patients and found radiotherapy for breast cancer is associated with a small but significantly increased risk of second cancers of the lung, esophagus, and soft tissues, but no significant association between radiotherapy and second thyroid cancer. Another research [14] containing 55,318 women from the National Health Insurance system of Taiwan, compared the risk of TC among BC patients who received radiotherapy or not, the risk to develop TC in women who received radiotherapy was not significantly higher than those not. Some other research based on different nations agreed with the opinion that radioactive iodine therapy did not significantly increase the incidence of subsequent BC risk to develop TC. As a clinician, when making medical decision for BC patients with these predictive factors, we should avoid to choose therapeutic methods those may increase the incidence of TC, which was the meaning for us to recognize these factors. In the previous study, Marcheselli et al. [2] demonstrated that human epidermal growth factor receptor 2 (HER-2) positivity, and BRCA1 or BRCA2 mutation had an effect on the risk of second primary neoplasms, but the effect was not limited to TC. These SIR influent factors in our manuscript are new with regard to the relationship between BC and TC. Regarding to the intensity of screening, as the highest excess risk was 1.61/10,000 in black women, a routine screening intensity is sufficient, however, clinicians should still consider the possibility of further developing TC in BC patients, especially individuals with black race, upper-out or central site tumor, high tumor grades, and both ER PR positive expression.

The present study demonstrated the clinicopathological features and survival of 842 BC patients followed by TC, represented a higher risk of TC development in BC
patients than in the general population, especially within 3 years, and the predictive factors of BC patients developing TC. The present study had some limitations. First, although population-based cancer registries provided a lot of information to the SEER database, data on HER-2 status were recorded only since 2010; therefore, among the 842 patients, only 68 had HER-2 records, which prevented the identification of the molecular subgroup of BC and may cause bias on the analyzing of HER-2. Second, this study was based on data from a database rather than data from research in a clinic, which might reduce the level of evidence. Further studies in the clinic and laboratory should be conducted to reveal more insights on the relationship of BC and TC.

Conclusions

BC patients who subsequently developed TC were more likely to be white and at a middle age, diagnosed with more T1 tumor, less lymph nodes metastasis, more infiltrating duct pathology, more 2 or 3 grade, and more hormone receptors positive disease. Compared with the features of BC only patients, they were younger, had a smaller tumor size, and had a relatively better prognosis. Additionally, age at the diagnosis of BC and the number of positive lymph nodes were prognostic factors to the OS of BC patients followed by TC after adjustment. Moreover, BC patients had a high risk of developing TC (SIR 1.22), especially within 3 years. Black women, primary tumor located in an upper-outter, central, or overlapping site, high grade tumor and with positive hormone receptors expression were risk factors of SIR, BC patients with these features showed an increased risk of TC development.

Abbreviations

BC: Breast cancer; CI: Confidence interval; ER: Estrogen receptor; HER-2: Human epidermal growth factor receptor 2; OR: Odds ratio; OS: Overall survival; PR: Progesterone receptor; SEER: Surveillance, Epidemiology, and End Results; SIR: Standardized incidence ratio; TC: Thyroid cancer

Acknowledgements

We would like to thank Editage for English language editing.

Authors’ contributions

LST analyzed and interpreted the data, was the major contributor in writing and revise the manuscript. YJ interpreted the data and was the writing assistance. SYW analyzed and interpreted the data, was the major contributor in writing and revise the manuscript. LST contributed to data analyzing. ZXA and ZLX were the major contributors to the manuscript. WYM helped to do publication decision. YM revised the first draft of the manuscript. The authors declare that they have no competing interests.

Author details

1Department of Medical Oncology, the First Affiliated Hospital of Xi’an Jiaotong University, 277 West Yanta Road, Xi’an 710061, Shaanxi, China. 2Department of Medical Oncology, Shaanxi Provincial Tumor Hospital, Xi’an, China. 3Department of Translational Medicine, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China.

Ethics approval and consent to participate

Not applicable. Data is available in a public database, ethics approval is not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359-86. https://doi.org/10.1002/ijc.29210 Epub 2014 Oct 9.

2. Marcheselli R, Marcheselli L, Cortesi L, Bari A, Crilli C, Pozzi S, et al. Risk of second primary malignancy in breast cancer survivors: a nested population-based case-control study. J Breast Cancer. 2015;18:378-85. https://doi.org/10.4048/jbc.2015.18.4.378.

3. An JH, Hwangbo Y, Ahn HY, Kean B, Lee KE, Han W, et al. A possible association between thyroid cancer and breast cancer. Thyroid. 2015;25:1330-8. https://doi.org/10.1089/thy.2014.0561 Epub 2015 Oct 27.

4. Grantzau T, Overgaard J. Risk of second non-breast cancer among patients treated with and without postoperative radiotherapy for primary breast cancer: a systematic review and meta-analysis of population-based studies including 522,739 patients. Radiother Oncol. 2016;121:402–13.

5. Raymond JS, Hogue C.J. Multiple primary tumours in women following breast cancer, 1973-2000. Br J Cancer. 2006;94:1745-50.

6. Evans HS, Lewis CM, Robinson D, Bell CM, Maller H, Hodgson SV. Incidence of multiple primary cancers in a cohort of women diagnosed with breast cancer in Southeast England. Br J Cancer. 2001;84(3):435–40.

7. Joseph KR, Edirimanne S, Ecklid GD. The association between breast cancer and thyroid cancer: a meta-analysis. Breast Cancer Res Treat. 2015;152:173–81. https://doi.org/10.1007/s10549-015-3456-6 Epub 2015 Jun 10.

8. Li J, Li Y, Meng Y, Wang Z, Cao X, Tan R, et al. Increased prevalence of breast cancer among patients with thyroid and parathyroid disease. Surgery. 2016;159:3–10. https://doi.org/10.1016/j.surg.2015.10.009 Epub 2015 Oct 29.

9. Garner CN, Ganetzky R, Brainard J, Hammel JP, Berger E, Siperstein AE, et al. Increased prevalence of breast cancer among patients with thyroid and parathyroid disease. Surgery. 2007;142:806–13.

10. Park CM, Lee YD, Oh EM, Kim K, Park HK, Ko KP, et al. The prognosis and treatment of primary thyroid cancer occurred in breast cancer patients: comparison with ordinary thyroid cancer. Ann Surg Treat Res. 2014;86:169–76. https://doi.org/10.4174/astr.2014.86.4.169.

11. Shi XZ, Jin X, Xu P, Shen HM. Relationship between breast cancer and levels of serum thyroid hormones and antibodies: a meta-analysis. Asian Pac J Cancer Prev. 2014;15(6):6643–7.

12. Beaton GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet. 1896;18:1047–4.

13. Liu YR, Jiang YZ, Yu KD, Shao ZM. Different patterns in the prognostic value of age for breast cancer-specific mortality depending on hormone receptor status: a SEER population-based analysis. Ann Surg Oncol. 2015;22:1102–10. https://doi.org/10.1245/sjo.2014.01.045.

14. Sun LW, Lin CL, Liang J, Huang WS, Kao CH. Radiotherapy did not increase thyroid cancer risk among women with breast cancer: a nationwide population-based cohort study. Int J Cancer. 2015;137;2896–903. https://doi.org/10.1002/ijc.29667 Epub 2015 Jul 14.
15. Yu GP, Schantz SP, Neugut AI, Zhang ZF. Incidences and trends of second cancers in female breast cancer patients: a fixed inception cohort-based analysis (United States). Cancer Causes Control. 2006;17(4):411–20.

16. Wei X, Li Y, Zhang S, Ming G. Evaluation of thyroid cancer in Chinese females with breast cancer by vascular endothelial growth factor (VEGF), microvesSEL density, and contrast-enhanced ultrasound (CEUS). Tumour Biol. 2014;35:6521–9. https://doi.org/10.1007/s13277-014-1868-2.

17. Lal G, Groff M, Howe JR, Sugg SL, Lynch CF. Risk of subsequent primary thyroid cancer after another malignancy: latency trends in a population-based study. Ann Surg Oncol. 2012;19:1887–96. https://doi.org/10.1245/s10434-011-1393-2.

18. Zhang Y, Liang J, Li H, Cong H, Lin Y. Risk of second primary breast cancer after radioactive iodine treatment in thyroid cancer: a systematic review and meta-analysis. Nucl Med Commun. 2016;37:110–5. https://doi.org/10.1097/MNM.0000000000000419.

19. Lin CY, Lin CL, Huang WS, Kao CH. Risk of breast cancer in patients with thyroid cancer receiving or not receiving I-131 treatment: a nationwide population-based cohort study. J Nucl Med. 2015;57:685–90. https://doi.org/10.2967/jnumed.115.164840.

20. Ahn HY, Min HS, Yeo Y, Ma SH, Hwang Y, An JH, et al. Radioactive iodine therapy did not significantly increase the incidence and recurrence of subsequent breast cancer. J Clin Endocrinol Metab. 2015;100:3486–93. https://doi.org/10.1210/jc.2014-2896.

21. Lin W, Ren FM, Ren ZF. The contribution of radiotherapy to subsequent thyroid cancer risk may be confined to a subgroup of breast cancer patients. Int J Cancer. 2016;138(7):1802. https://doi.org/10.1002/ijc.29907.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.